Cargando…

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies

Neoantigen-specific T cells are strongly implicated as being critical for effective immune checkpoint blockade treatment (ICB) (e.g., anti–PD-1 and anti–CTLA-4) and are being targeted for vaccination-based therapies. However, ICB treatments show uneven responses between patients, and neoantigen vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shamin, Simoni, Yannick, Zhuang, Summer, Gabel, Austin, Ma, Shaokang, Chee, Jonathan, Islas, Laura, Cessna, Anthony, Creaney, Jenette, Bradley, Robert K., Redwood, Alec, Robinson, Bruce W., Newell, Evan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2021
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325261/ https://www.ncbi.nlm.nih.gov/pubmed/34285073 http://dx.doi.org/10.1073/pnas.2025570118

Ejemplares similares

What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
por: Redwood, Alec J., et al.
Publicado: (2022)

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
por: Robinson, Bruce W.S., et al.
Publicado: (2022)

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
por: Ma, Shaokang, et al.
Publicado: (2019)

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
por: Creaney, Jenette, et al.
Publicado: (2015)

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2019)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Bystander CD4(+) T cells infiltrate human tumors and are phenotypically distinct
por: Li, Shamin, et al.
Publicado: (2022)

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells
por: Fehlings, M., et al.
Publicado: (2017)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells
por: Fehlings, M., et al.
Publicado: (2018)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Association of Biomarker Levels with Severity of Asbestos-Related Diseases
por: Park, Eun-Kee, et al.
Publicado: (2012)

Transient Treg depletion enhances therapeutic anti‐cancer vaccination
por: Fisher, Scott A., et al.
Publicado: (2016)

Neoantigen Tracking: Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer (Adv. Sci. 9/2020)
por: Jia, Qingzhu, et al.
Publicado: (2020)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
por: Robinson, Cleo, et al.
Publicado: (2015)

Partial absence of PD‐1 expression by tumor‐infiltrating EBV‐specific CD8(+) T cells in EBV‐driven lymphoepithelioma‐like carcinoma
por: Simoni, Yannick, et al.
Publicado: (2020)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
por: Anzar, Irantzu, et al.
Publicado: (2023)

Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
por: Wang, Wenwen, et al.
Publicado: (2022)

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
por: Jia, Qingzhu, et al.
Publicado: (2020)

NeoFox: annotating neoantigen candidates with neoantigen features
por: Lang, Franziska, et al.
Publicado: (2021)

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
por: Repáraz, David, et al.
Publicado: (2022)

Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
por: Lang, Franziska, et al.
Publicado: (2023)

Lymphoma neoantigens
por: Elias, Joshua E.
Publicado: (2018)

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
por: Chee, Jonathan, et al.
Publicado: (2018)

Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
por: Fear, Vanessa S., et al.
Publicado: (2021)

Correction to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
por: Fear, Vanessa S., et al.
Publicado: (2021)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
por: D’Alise, Anna Morena, et al.
Publicado: (2019)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
por: Shen, Luhui, et al.
Publicado: (2023)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2017)

Determinants for Neoantigen Identification
por: Garcia-Garijo, Andrea, et al.
Publicado: (2019)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Calretinin as a blood-based biomarker for mesothelioma
por: Johnen, Georg, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f68dq6dqa2ccponb9j5qcb8lu8